Galapagos NV (Galapagos NV) Change In Receivables : $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Change In Receivables?

Galapagos NV's change in receivables for the quarter that ended in Dec. 2023 was $0.0 Mil. It means Galapagos NV's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Galapagos NV's change in receivables for the fiscal year that ended in Dec. 2023 was $-42.7 Mil. It means Galapagos NV's Accounts Receivable increased by $42.7 Mil from Dec. 2022 to Dec. 2023 .

Galapagos NV's Accounts Receivable for the quarter that ended in Dec. 2023 was $19.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Galapagos NV's liquidation value for the three months ended in Dec. 2023 was $2,369.4 Mil.

Galapagos NV Change In Receivables Historical Data

The historical data trend for Galapagos NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Change In Receivables Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-74.74

-215.52

90.24

73.08

-42.65

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															5.81	-	-	-	-

Galapagos NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Galapagos NV (NAS:GLPG) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Galapagos NV's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	19.077	/	-228.052	*	91
=

2. In Ben Graham's calculation of liquidation value, Galapagos NV's accounts receivable are only considered to be worth 75% of book value:

Galapagos NV's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4017.995	-	1703.195	+	0.75 * 19.077	+	0.5 * 80.674
=	2,369.4

Galapagos NV Change In Receivables Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.